321 related articles for article (PubMed ID: 33881722)
1. Emerging urinary alpha-synuclein and miRNA biomarkers in Parkinson's disease.
Giri B; Seamon M; Banerjee A; Chauhan S; Purohit S; Morgan J; Baban B; Wakade C
Metab Brain Dis; 2022 Aug; 37(6):1687-1696. PubMed ID: 33881722
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers of Parkinson's disease: present and future.
Miller DB; O'Callaghan JP
Metabolism; 2015 Mar; 64(3 Suppl 1):S40-6. PubMed ID: 25510818
[TBL] [Abstract][Full Text] [Related]
3. High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases.
Bougea A; Stefanis L; Emmanouilidou E; Vekrelis K; Kapaki E
J Neural Transm (Vienna); 2020 Mar; 127(3):311-322. PubMed ID: 31912280
[TBL] [Abstract][Full Text] [Related]
4. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
[TBL] [Abstract][Full Text] [Related]
5. miRNA in Parkinson's disease: From pathogenesis to theranostic approaches.
Elangovan A; Venkatesan D; Selvaraj P; Pasha MY; Babu HWS; Iyer M; Narayanasamy A; Subramaniam MD; Valsala Gopalakrishnan A; Kumar NS; Vellingiri B
J Cell Physiol; 2023 Feb; 238(2):329-354. PubMed ID: 36502506
[TBL] [Abstract][Full Text] [Related]
6. A review of the current research on in vivo and in vitro detection for alpha-synuclein: a biomarker of Parkinson's disease.
Wang R; Pang SC; Li JY; Li CL; Liu JM; Wang YM; Chen ML; Li YB
Anal Bioanal Chem; 2023 Apr; 415(9):1589-1605. PubMed ID: 36688984
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers in Parkinson's disease (recent update).
Sharma S; Moon CS; Khogali A; Haidous A; Chabenne A; Ojo C; Jelebinkov M; Kurdi Y; Ebadi M
Neurochem Int; 2013 Sep; 63(3):201-29. PubMed ID: 23791710
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
[TBL] [Abstract][Full Text] [Related]
9. Novel insights into the role of circular RNAs in Parkinson disease: An emerging renaissance in the management of neurodegenerative diseases.
Dorostgou Z; Yadegar N; Dorostgou Z; Khorvash F; Vakili O
J Neurosci Res; 2022 Sep; 100(9):1775-1790. PubMed ID: 35642104
[TBL] [Abstract][Full Text] [Related]
10. Brain-Biomarker Changes in Body Fluids of Patients with Parkinson's Disease.
Cocco C; Manai AL; Manca E; Noli B
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446110
[TBL] [Abstract][Full Text] [Related]
11. The value of cerebrospinal fluid α-synuclein and the tau/α-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology.
Førland MG; Tysnes OB; Aarsland D; Maple-Grødem J; Pedersen KF; Alves G; Lange J
Eur J Neurol; 2020 Jan; 27(1):43-50. PubMed ID: 31293044
[TBL] [Abstract][Full Text] [Related]
12. [Non-motor symptoms of Parkinson's disease from pathophysiology to early diagnosis].
Aubignat M; Tir M; Krystkowiak P
Rev Med Interne; 2021 Apr; 42(4):251-257. PubMed ID: 32680717
[TBL] [Abstract][Full Text] [Related]
13. MALAT1 lncRNA and Parkinson's Disease: The role in the Pathophysiology and Significance for Diagnostic and Therapeutic Approaches.
Abrishamdar M; Jalali MS; Rashno M
Mol Neurobiol; 2022 Sep; 59(9):5253-5262. PubMed ID: 35665903
[TBL] [Abstract][Full Text] [Related]
14. Salivary Biomarkers for Parkinson's Disease: A Systematic Review with Meta-Analysis.
Nijakowski K; Owecki W; Jankowski J; Surdacka A
Cells; 2024 Feb; 13(4):. PubMed ID: 38391952
[TBL] [Abstract][Full Text] [Related]
15. The understanding of Parkinson's disease through genetics and new therapies.
Uwishema O; Onyeaka H; Badri R; Yücel AN; Korkusuz AK; Ajagbe AO; Abuleil A; Chaaya C; Alhendawi BHM; Chalhoub E
Brain Behav; 2022 May; 12(5):e2577. PubMed ID: 35451243
[TBL] [Abstract][Full Text] [Related]
16. The central theme of Parkinson's disease: α-synuclein.
Ozansoy M; Başak AN
Mol Neurobiol; 2013 Apr; 47(2):460-5. PubMed ID: 23180276
[TBL] [Abstract][Full Text] [Related]
17. Behavioral defects associated with amygdala and cortical dysfunction in mice with seeded α-synuclein inclusions.
Stoyka LE; Arrant AE; Thrasher DR; Russell DL; Freire J; Mahoney CL; Narayanan A; Dib AG; Standaert DG; Volpicelli-Daley LA
Neurobiol Dis; 2020 Feb; 134():104708. PubMed ID: 31837424
[TBL] [Abstract][Full Text] [Related]
18. Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson's disease.
Doppler K; Jentschke HM; Schulmeyer L; Vadasz D; Janzen A; Luster M; Höffken H; Mayer G; Brumberg J; Booij J; Musacchio T; Klebe S; Sittig-Wiegand E; Volkmann J; Sommer C; Oertel WH
Acta Neuropathol; 2017 Apr; 133(4):535-545. PubMed ID: 28180961
[TBL] [Abstract][Full Text] [Related]
19. Human amyloid beta and α-synuclein co-expression in neurons impair behavior and recapitulate features for Lewy body dementia in Caenorhabditis elegans.
Huang X; Wang C; Chen L; Zhang T; Leung KL; Wong G
Biochim Biophys Acta Mol Basis Dis; 2021 Oct; 1867(10):166203. PubMed ID: 34146705
[TBL] [Abstract][Full Text] [Related]
20. Methods for detecting toxic α-synuclein species as a biomarker for Parkinson's disease.
O'Hara DM; Kalia SK; Kalia LV
Crit Rev Clin Lab Sci; 2020 Aug; 57(5):291-307. PubMed ID: 32116096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
